ScreenerHero

APLM Apollomics, Inc.

NAS · US · Healthcare · Biotechnology · apollomicsinc.com
21.50USD-2.71%Mkt Cap: 62.67M $P/E: —

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The comp…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap62.67M USD
Enterprise Value45.90M USD
Revenue (TTM)8.84M USD
Gross Profit8.84M USD
Net Income (TTM)-10.94M USD
Revenue/Share6.12 USD
Last Price21.50 USD
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees14
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-34.00
PEG—
EV/EBITDA-5.05
EV/Revenue5.19
P/S7.29
P/B-14.88
EPS (TTM)-7.57
EPS (Forward)-0.65
52W Range
10.0136% of range42.12
52W High42.12 USD
52W Low10.01 USD
Profitability
Gross Margin100.00%
Oper. Margin431.87%
EBITDA Margin-102.75%
Profit Margin-128.69%
ROE343.13%
ROA-162.93%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-10.37M USD
CapEx (TTM)—
FCF Margin-110.93%
FCF Yield-15.65%
Net Debt-2.63M USD
Net Debt/EBITDA0.29
Balance Sheet
Debt/Equity-0.20
Current Ratio0.96
Quick Ratio0.91
Book Value/Sh-1.49 USD
Cash/Share1.49 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:100
Split DateNov 25, 2024
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.2.91M
Float535.00K
Insiders56.46%
Institutions0.42%
Short Interest
Short Ratio0.5d
Short % Float0.31%
Short % Out.0.19%
Shares Short5.64K
Short (prev mo.)6.08K
Technical
SMA 5022.48 (-4.4%)
SMA 20018.76 (+14.6%)
Beta1.54
S&P 52W Chg16.45%
Avg Vol (30d)11.62K
Avg Vol (10d)8.41K
Technical Indicators
RSI (14)42.4
MACD0.0598
MACD Signal0.4700
MACD Hist.-0.4102
BB Upper26.18 USD
BB Middle23.72 USD
BB Lower21.27 USD
BB Width20.72%
ATR (14)1.644 USD
Vol Ratio (20d)0.61x